Compare Centrus Energy Corp (LEU) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centrus Energy Corp vs Recursion Pharmaceuticals Inc — how do they compare? Centrus Energy Corp trades at $142.44 (market cap $2.91B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Centrus Energy Corp is the larger of the two by market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Centrus Energy Corp for 29 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| LEU | RXRX | |
|---|---|---|
Market Cap | $2.91B | $2.14B |
Volume | 903,777 | 30,789,535 |
Sector | Energy | Health |
52-Week High | $436.00 | $6.79 |
52-Week Low | $138.18 | $2.84 |
Typical Hold Time | 29 Days | 23 Days |
Enterprise Value | $2.22B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Centrus Energy (LEU) trades at $142.44, down 3.19% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows elevated valuation metrics (P/E 75.18, P/S 6.68) while profitability metrics remain solid (net margin 10.23%, ROE 8.05%). Recent news highlights the company's strategic position as a key HALEU supplier amid growing nuclear energy demand, with multiple new supply contracts announced in September 2026.
LEU presents a high-risk, high-reward opportunity with analyst consensus price target of $218.10 (53% upside) but significant execution risks. The company's growth depends on successful expansion of domestic uranium enrichment capacity and capitalizing on nuclear energy tailwinds, though recent profit margin compression and negative operating cash flow projections for 2026 warrant caution.
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
